InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,267.84
(
-0.74%
)
US TECH 100
18,150.00
(
-0.43%
)
Dow Jones
39,065.26
(
-1.53%
)
Brent Oil
81.14
(
-0.21%
)
Bitcoin
67,585.00
(
-0.50%
)
Post# of 255
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

georgejjl

Send PM Follow Ignore
Followers 138
Posts 22969
Boards Moderated 0
Alias Born 04/08/2004

georgejjl

Re: None

Wednesday, 09/22/2021 4:43:42 PM

Wednesday, September 22, 2021 4:43:42 PM

Post# of 255
we expect to report 12-month topline safety, biomarker, and clinical outcomes data from the Type II low-dose cohort of AXO-AAV-GM1 in October 2021.”

https://investors.siogtx.com/news-releases/news-release-details/sio-gene-therapies-announces-dosing-first-gm1-gangliosidosis

Good luck and GOD bless,
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up